human ccl21 δc (Innovative Research Inc)
Structured Review

Human Ccl21 δc, supplied by Innovative Research Inc, used in various techniques. Bioz Stars score: 94/100, based on 2 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human ccl21 δc/product/Innovative Research Inc
Average 94 stars, based on 2 article reviews
Images
1) Product Images from "uPA-mediated remodeling of CCL21 gradients regulates lymphatic migration of dendritic cells"
Article Title: uPA-mediated remodeling of CCL21 gradients regulates lymphatic migration of dendritic cells
Journal: The Journal of Cell Biology
doi: 10.1083/jcb.202412190
Figure Legend Snippet: A soluble proteoform of CCL21 (CCL21-ΔC) with chemotactic activity is present in murine skin and increased in CHS-inflamed skin. (A) Representative western blot of CCL21 performed on steady-state (CTR) and CHS-inflamed (CHS) murine ear skin protein extracts. Recombinant CCL21 was loaded as a CTR. (B) Western blot analysis of recombinant human full-length CCL21 and CCL21-ΔC protein. One out of two experiments is shown. (C) Quantification of the full-length CCL21 (gray) and CCL21-ΔC (white) relative band percentages. Pooled data from n = 4 independent biological replicates. (D) ELISA-based quantification of total CCL21 in tissue protein extracts, performed with antibody clone AF457, which detects full-length CCL21 and CCL21-ΔC. Pooled data from n = 5 mice/condition. Statistics: unpaired Student’s t test. (E–J) Skin elution assay and analyses were performed on the supernatants. (E) Schematic depiction of the assay and representative western blot analysis. (F) Image-based quantification of the CCL21-ΔC band intensity from western blots as in E. A.U., arbitrary units, as produced by the western blot imager (G) ELISA-based quantification of total CCL21, performed with antibody clone AF457. Pooled data from n = 6–7 mice/condition, with one CHS-inflamed and a contralateral CTR ear, are shown in E and F. Data from the same mouse are connected by a line. The mean is shown in red, paired Student’s t test. (H–J) Transwell chemotaxis assays were performed on elution assay supernatants (see E) with 1:1 mixtures of LPS-matured labelled WT and CCR7 −/− DCs in presence/absence of a CCL21-blocking antibody. Flow cytometry–based quantification of the total numbers of transmigrated (H) WT DCs and (I) CCR7 −/− DCs, as well as of (J) the ratio of transmigrated WT to CCR7 −/− DCs. Data points from 3–7 experiments per condition are shown. Mixed effects statistical analysis. (K) Ratio of WT: CCR7 −/− DCs measured in seven paired experiments performed for CTR and CHS-inflamed condition. Statistical analysis: paired Student's t test. (L and M) Western blot analysis of protein extracts of (L) steady-state human skin (CTR) and (M) donor-matched steady-state (CTR) and inflamed (INF) human skin from a psoriasis patient. Data from one out of two experiments in L and one experiment in M are shown. Recombinant human full-length CCL21 was loaded as a CTR. Source data are available for this figure: .
Techniques Used: Activity Assay, Western Blot, Recombinant, Enzyme-linked Immunosorbent Assay, Produced, Chemotaxis Assay, Blocking Assay, Flow Cytometry
Figure Legend Snippet: LECs activate plasminogen to plasmin, thereby generating CCL21-ΔC with enhanced chemotactic activity. (A and B) Quantification of (A) plasminogen and (B) plasmin activity in tissue protein extracts generated from CTR or CHS-inflamed ear skin. n = 6–7 mice per condition. (C) CTR experiment with CHS-inflamed ears documenting that the plasmin activity observed in C can be completely blocked in presence of the plasmin inhibitor C3. (D) Schematic depiction of the experimental hypothesis: Inflammation leads to enhanced extravasation of plasminogen. uPA bound to uPAR on CCL21-secreting LECs converts plasminogen to plasmin, thereby inducing CCL21 cleavage into CCL21-ΔC. (E–G) In vitro CCL21 cleavage experiment: (E) Schematic depiction of the experiment: immortalized LECs were incubated with recombinant CCL21 (100 nM) and plasminogen (20 nM) for 4 h or 24 h at 37°C in absence or presence of the plasmin inhibitor C3, mU1, or PIC. Supernatants were analyzed by western blot for CCL21. (F) Representative western blot of the cell culture supernatant at indicated time points and conditions and (G) quantification of the full-length CCL21 (gray) and CCL21-ΔC (white) relative band percentage. Pooled data from n = 4 independent experiments. Mean ± SEM, one-way ANOVA, and P values are relative to the “plg only” condition. (H and I) Cell culture supernatants generated as in E were evaluated in a 3D collagen migration assay. Recombinant human CCL21 and CCL21-ΔC were used as positive CTRs (H) Cell trajectory plots of migrating BMDCs’ migratory tracks in response to the stimuli applied on either side of the collagen channel. (I) Quantification of DC directionality, displacement, and velocity in response to the stimuli applied. Pooled data from n = 2 independent experiments with a total of n = 40–50 tracks analyzed per condition. Mean ± SEM, unpaired Student's t test for each comparison. (J–L) Analysis of the CCL21 cleavage activity of LECs isolated from uPA −/− mice or mice with defective uPA binding to uPAR (uPA mut ) (J) Schematic illustration of the three genotypes investigated. (K and L) Representative western blot of the cell culture supernatants after (K) 4 h and (L) 24 h of incubation (top) and quantification of the full-length CCL21 (gray) and CCL21-ΔC (white) relative band percentage (bottom). Pooled data from n = 5 independent experiments. Mean ± SEM, one-way ANOVA, and Source data are available for this figure: . plg, plasminogen.
Techniques Used: Activity Assay, Generated, In Vitro, Incubation, Recombinant, Western Blot, Cell Culture, Migration, Comparison, Isolation, Binding Assay
Figure Legend Snippet: Video showing fluorescently labeled bone marrow–derived DCs (green) moving in 3D collagen toward recombinant human CCL21 (up) and CCL21+plg (down) provided in reservoirs on left and right, respectively, of the chamber. WT DCs display enhanced migration toward CCL21-ΔC provided on the left. Video specifications: 5-min intervals; 5 frames/s (1500-fold accelerated). The original length of the recording: 200 min. Video length: 8 s. plg, plasminogen.
Techniques Used: Labeling, Derivative Assay, Recombinant, Migration
Figure Legend Snippet: Impact of plasmin and plasmin(ogen) on in vitro DC migration. In vitro experiments were performed with LPS-matured bone marrow–derived DCs and primary LN LECs. (A) DC displayed greater chemotaxis toward CCL21-ΔC as compared with full-length CCL21. (B) DCs were allowed to transmigrate for 4 h across primary LN LEC monolayers. DCs displayed a near-significant in transmigration (i.e., in two out of three experiments) toward CCL21-ΔC compared with CCL21 added to the lower well compartment. (C and D) The presence of plasminogen (Plg) or plasmin (Plm), which were added to the upper and lower wells of the Transwell plate, did not impact DC chemotaxis toward (C) CCL21-ΔC and (D) CXCL12. Each data point represents an independent experiment. (E and F) The presence of plasminogen or plasmin in the assay (upper and lower wells) did not impact DC transmigration across LEC monolayers toward (E) CCL21-ΔC or (F) CXCL12. Each data point represents an independent experiment. (G and H) Crawling assay: YFP-expressing DCs were added on top of LEC monolayers, and their migration was recorded by time-lapse microscopy. The presence of plasminogen or plasmin in the medium did not impact the (G) velocity and (H) chemotactic index of DC crawling. Of note: Inhibition of ROCK with Y27632 was performed as positive CTR . Statistics: two-way ANOVA using multiple comparisons, followed by a Tukey correction. (I) qPCR-results demonstrating that in vitro –cultured primary LN LECs no longer express CCL21 and also do not express CCL19. S18: housekeeping gene; gp38: podoplanin. Raw CT values are shown. n = 3 different biological replicates (isolations).
Techniques Used: In Vitro, Migration, Derivative Assay, Chemotaxis Assay, Transmigration Assay, Expressing, Time-lapse Microscopy, Inhibition, Cell Culture
Figure Legend Snippet: Blockade of uPA or plasmin activity alters the perilymphatic CCL21 gradient. (A) Representative images showing LYVE-1 and the immobilized perilymphatic CCL21 gradient in the steady-state ear skin of WT, uPA mut and uPA −/− , ACKR4 −/− , and CCR7 −/− mice. Scale bar: 50 μm. (B) Quantification of the CCL21 staining intensity as a function of the distance from the nearest LYVE-1 + LV. n = 4–6 mice per condition, two-way ANOVA (C and D) Quantification of the CCL21 staining intensity at (C) 0 μm or 30 μm from the LV. (E) Ratio of the CCL21 signal intensity measured at 60 vs. 0 μm from the LV. n = 4–6 mice per condition; one-way ANOVA. (F) ELISA-based quantification of total CCL21 in culture supernatants from ear skin of WT and uPA mut mice, performed with antibody clone AF457 which detects full-length CCL21 and CCL21-ΔC. Pooled data from n = 4 mice/condition. Statistics: unpaired Student's t test. (G–J) Impact of 24 h of combined treatment with the plasmin-selective inhibitor C3 and uPA-blocking antibody mU1 on the perilymphatic CCL21 gradient. (G) Representative images showing the CCL21 and LYVE-1 signal in the ear skin of mice. Scale bar: 50 μm. (H) Quantification of the CCL21 staining intensity as a function of the distance from the nearest LYVE-1 + LV. Two-way ANOVA, n = 3 mice. (I and J) Quantification of the CCL21 staining intensity at (I) 0 μm or (J) 30 μm from the LV. n = 3 mice per condition. Paired Student’s t test.
Techniques Used: Activity Assay, Staining, Enzyme-linked Immunosorbent Assay, Blocking Assay
Figure Legend Snippet: Blockade of uPA results in reduced CCL21-ΔC levels in skin-dLNs. (A and B) Western blot–based comparison of CCL21 proteoforms in steady-state LNs and ear skin. (A) Representative western blots performed on tissue protein extracts and (B) and quantification of the full-length CCL21 (gray) and CCL21-ΔC (white) relative band percentages. Pooled data from n = 4 western blots from independent experiments. (C) Representative western blot of CCL21 performed on LN extracts, LN eluates, and serum. (D) ELISA-based quantification of full-length CCL21 and CCL21-ΔC present in LN extracts, LN eluates, or serum. Antibody clone MAB457 detects full-length CCL21 only, whereas clone AF457 detects both full-length CCL21 and CCL21-ΔC. Data from n = 3 mice are shown. n.d., not detected. (E) ELISA-based quantification of full-length CCL21 and CCL21-ΔC present in LN eluates from WT and uPA mut mice. Data from n = 4–5 mice are shown, Student’s t test. n.d., not detected. (F and G) Protein extracts were prepared from LNs of PBS-perfused WT and uPA mut mice and used for ELISA-based quantification of (F) plasminogen and (G) assessment of plasmin activity (colorimetric assay). Pooled data from n = 6 mice per group are shown as mean ± SEM. Student’s t test. (H and I) Analysis of CCL21 levels in LNs of WT and uPA mut mice. Freshly cut LN sections were immediately (i.e., without fixation/permeabilization) stained for B220 (B cell follicles), LYVE-1, and CCL21. Images were subjected to AI-based tissue segmentation for differentiating between the T cell zone and B cell follicles/SCS. (H) Representative images from the immunofluorescent staining performed on LNs of WT and uPA mut mice. Scale bar: 100 μm. (I) Quantification of CCL21 staining intensity observed in the T cell zone. Each dot represents data from a stained auricular LN of one mouse (average of 4–6 images per LN). Student’s t test. Source data are available for this figure: .
Techniques Used: Western Blot, Comparison, Enzyme-linked Immunosorbent Assay, Activity Assay, Colorimetric Assay, Staining
Figure Legend Snippet: Summary diagram. Summary of the main findings and the overall model. Top: Summary of events happening at the level of LECs: continuous low-level extravasation of plasminogen from blood vessels leads to uPA/uPAR-mediated activation of plasmin, which in turn cleaves immobilized CCL21 into soluble CCL21-ΔC (WT steady-state—left). When uPA-mediated activation of plasminogen is compromised (uPA mut ), less CCL21 gets cleaved, shifting the balance toward more immobilized CCL21 accumulating on/around LECs (uPA mut steady-state—middle). Under inflammatory conditions, with higher extravasation of plasminogen and higher expression of uPA and uPAR by LECs, more plasmin is activated, resulting in more CCL21 cleavage (WT inflammation—right). Bottom: The bottom part of the figure illustrates how these changes affect the balance between immobilized CCL21 and soluble CCL21-ΔC around afferent lymphatics and in the dLN. Additionally, the impact on distinct CCR7-dependent steps (1–3) in lymphatic migration of DCs are indicated. Question marks (?) indicate steps that were not specifically investigated in this study and thus represent speculations based on indirect findings and/or the literature.
Techniques Used: Activation Assay, Expressing, Migration
